252 related articles for article (PubMed ID: 29167827)
1. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?
Lerut J; Iesari S; Foguenne M; Lai Q
Transl Gastroenterol Hepatol; 2017; 2():80. PubMed ID: 29167827
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
3. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
Rodríguez-Perálvarez M; Tsochatzis E; Naveas MC; Pieri G; García-Caparrós C; O'Beirne J; Poyato-González A; Ferrín-Sánchez G; Montero-Álvarez JL; Patch D; Thorburn D; Briceño J; De la Mata M; Burroughs AK
J Hepatol; 2013 Dec; 59(6):1193-9. PubMed ID: 23867318
[TBL] [Abstract][Full Text] [Related]
4. Tailored long-term immunosuppressive regimen for adult liver transplant recipients with hepatocellular carcinoma.
Kang SH; Hwang S; Ha TY; Song GW; Jung DH; Kim KH; Ahn CS; Moon DB; Park GC; Jung BH; Yoon YI; Lee SG
Korean J Hepatobiliary Pancreat Surg; 2014 May; 18(2):48-51. PubMed ID: 26155248
[TBL] [Abstract][Full Text] [Related]
5. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Grigg SE; Sarri GL; Gow PJ; Yeomans ND
Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
[TBL] [Abstract][Full Text] [Related]
6. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
8. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
10. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
12. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.
Sposito C; Cucchetti A; Mazzaferro V
Dig Dis Sci; 2019 Apr; 64(4):1001-1007. PubMed ID: 30852770
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.
Yang PC; Ho CM; Hu RH; Ho MC; Wu YM; Lee PH
World J Hepatol; 2016 Nov; 8(31):1309-1317. PubMed ID: 27872682
[TBL] [Abstract][Full Text] [Related]
14. Developments in liver transplantation for hepatocellular carcinoma.
Melloul E; Lesurtel M; Carr BI; Clavien PA
Semin Oncol; 2012 Aug; 39(4):510-21. PubMed ID: 22846868
[TBL] [Abstract][Full Text] [Related]
15. Trough Levels of Everolimus Are Associated With Recurrence Rates of Hepatocellular Carcinoma After Liver Transplantation.
Cholongitas E; Antoniadis N; Goulis I; Theocharidou E; Ιmvrios G; Giouleme O; Filis D; Mouloudi E; Akriviadis E; Fouzas I
Transplant Proc; 2019 Mar; 51(2):450-453. PubMed ID: 30879564
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience.
Cholongitas Ε; Goulis I; Theocharidou E; Antoniadis N; Fouzas I; Giakoustidis D; Imvrios G; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Hepatol Int; 2014 Jan; 8(1):137-45. PubMed ID: 26202415
[TBL] [Abstract][Full Text] [Related]
17. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
18. Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?
Angelico R; Parente A; Manzia TM
Transl Gastroenterol Hepatol; 2017; 2():74. PubMed ID: 29034347
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
20. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation.
Pelizzaro F; Gambato M; Gringeri E; Vitale A; Cillo U; Farinati F; Burra P; Russo FP
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
